BMS-214662

• Description:

  BMS-214662 is a farnesyl transferase inhibitor. BMS-214662 can effectively block the localization and function of Ras protein in the cell membrane by inhibiting the pro-group modification of Ras protein, thereby exerting anti-tumor activity. BMS-214662 has an IC50 value of 1.3 nM for H-Ras and 8.4 nM for K-Ras. BMS-214662 can be used to study Ras-related tumor diseases[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319

• Target:

  Farnesyl Transferase; Ras

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; MAPK/ERK Pathway; Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/BMS-214662.html

• Purity:

  99.86

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  N#CC1=CC=C (N (CC2=CN=CN2) C[C@@H] (CC3=CC=CC=C3) N (S (=O) (C4=CC=CS4) =O) C5) C5=C1

• Molecular Formula:

  C25H23N5O2S2

• Molecular Weight:

  489.61

• Precautions:

  H302, H315, H319

• References & Citations:

  [1]Hunt JT, et al. Discovery of (R) -7-cyano-2,3,4, 5-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3- (phenylmethyl) -4- (2-thienylsulfonyl) -1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. J Med Chem. 2000 Oct 5;43 (20) :3587-95.|[2]Rose WC, et al. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 2001 Oct 15;61 (20) :7507-17.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  195987-41-8